vs
Side-by-side financial comparison of BOSTON BEER CO INC (SAM) and Bio-Techne (TECH). Click either name above to swap in a different company.
BOSTON BEER CO INC is the larger business by last-quarter revenue ($461.6M vs $311.4M, roughly 1.5× Bio-Techne). On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -4.1%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -10.7%).
The Boston Beer Company is an American brewery founded in 1984 by James "Jim" Koch and Rhonda Kallman. Boston Beer Company's first brand of beer was named Samuel Adams after Founding Father Samuel Adams, an American revolutionary patriot. Since its founding, Boston Beer has started several other brands, and in 2019 completed a merger with Dogfish Head Brewery.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SAM vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $461.6M | $311.4M |
| Net Profit | — | $51.0M |
| Gross Margin | 46.4% | 66.9% |
| Operating Margin | 12.4% | 24.2% |
| Net Margin | — | 16.4% |
| Revenue YoY | -4.1% | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | $2.16 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $461.6M | $311.4M | ||
| Q4 25 | $385.7M | $295.9M | ||
| Q3 25 | $537.5M | — | ||
| Q2 25 | $587.9M | $317.0M | ||
| Q1 25 | $453.9M | $316.2M | ||
| Q4 24 | $402.3M | $297.0M | ||
| Q3 24 | $605.5M | $289.5M | ||
| Q2 24 | $579.1M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $-22.5M | $38.0M | ||
| Q3 25 | $46.2M | — | ||
| Q2 25 | $60.4M | $-17.7M | ||
| Q1 25 | $24.4M | $22.6M | ||
| Q4 24 | $-38.8M | $34.9M | ||
| Q3 24 | $33.5M | $33.6M | ||
| Q2 24 | $52.3M | $40.6M |
| Q1 26 | 46.4% | 66.9% | ||
| Q4 25 | 43.5% | 64.6% | ||
| Q3 25 | 50.8% | — | ||
| Q2 25 | 49.8% | 62.7% | ||
| Q1 25 | 48.3% | 67.9% | ||
| Q4 24 | 39.9% | 65.3% | ||
| Q3 24 | 46.3% | 63.2% | ||
| Q2 24 | 46.0% | 66.4% |
| Q1 26 | 12.4% | 24.2% | ||
| Q4 25 | -8.6% | 18.4% | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | 14.0% | -7.5% | ||
| Q1 25 | 7.4% | 12.2% | ||
| Q4 24 | -13.9% | 16.0% | ||
| Q3 24 | 7.6% | 13.8% | ||
| Q2 24 | 12.2% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | -5.8% | 12.8% | ||
| Q3 25 | 8.6% | — | ||
| Q2 25 | 10.3% | -5.6% | ||
| Q1 25 | 5.4% | 7.1% | ||
| Q4 24 | -9.6% | 11.7% | ||
| Q3 24 | 5.5% | 11.6% | ||
| Q2 24 | 9.0% | 13.3% |
| Q1 26 | $2.16 | $0.32 | ||
| Q4 25 | $-1.97 | $0.24 | ||
| Q3 25 | $4.25 | — | ||
| Q2 25 | $5.45 | $-0.11 | ||
| Q1 25 | $2.16 | $0.14 | ||
| Q4 24 | $-3.23 | $0.22 | ||
| Q3 24 | $2.86 | $0.21 | ||
| Q2 24 | $4.39 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $164.1M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $682.6M | $2.1B |
| Total Assets | $1.2B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $164.1M | $209.8M | ||
| Q4 25 | $223.4M | $172.9M | ||
| Q3 25 | $250.5M | — | ||
| Q2 25 | $212.4M | $162.2M | ||
| Q1 25 | $152.5M | $140.7M | ||
| Q4 24 | $211.8M | $177.5M | ||
| Q3 24 | $255.6M | $187.5M | ||
| Q2 24 | $219.3M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $682.6M | $2.1B | ||
| Q4 25 | $846.3M | $2.0B | ||
| Q3 25 | $911.0M | — | ||
| Q2 25 | $912.3M | $1.9B | ||
| Q1 25 | $897.0M | $2.0B | ||
| Q4 24 | $916.2M | $2.1B | ||
| Q3 24 | $1.0B | $2.1B | ||
| Q2 24 | $1.0B | $2.1B |
| Q1 26 | $1.2B | $2.6B | ||
| Q4 25 | $1.2B | $2.5B | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.2B | $2.6B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $1.4B | $2.7B | ||
| Q2 24 | $1.4B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SAM
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
